Your browser doesn't support javascript.
loading
Gain-of-function mutations in DNMT3A in patients with paraganglioma.
Remacha, Laura; Currás-Freixes, Maria; Torres-Ruiz, Raúl; Schiavi, Francesca; Torres-Pérez, Rafael; Calsina, Bruna; Letón, Rocío; Comino-Méndez, Iñaki; Roldán-Romero, Juan M; Montero-Conde, Cristina; Santos, María; Pérez, Lucía Inglada; Pita, Guillermo; Alonso, María R; Honrado, Emiliano; Pedrinaci, Susana; Crespo-Facorro, Benedicto; Percesepe, Antonio; Falcioni, Maurizio; Rodríguez-Perales, Sandra; Korpershoek, Esther; Ramón-Maiques, Santiago; Opocher, Giuseppe; Rodríguez-Antona, Cristina; Robledo, Mercedes; Cascón, Alberto.
  • Remacha L; Hereditary Endocrine Cancer Group, Spanish National Cancer Research Centre (CNIO), Madrid, Spain.
  • Currás-Freixes M; Hereditary Endocrine Cancer Group, Spanish National Cancer Research Centre (CNIO), Madrid, Spain.
  • Torres-Ruiz R; Molecular Cytogenetics Unit, Human Cancer Genetics Programme, Spanish National Cancer Research Centre (CNIO), Madrid, Spain.
  • Schiavi F; Veneto Institute of Oncology, Istituto di Ricovero e Cura a Carattere Scientifico, Padua, Italy.
  • Torres-Pérez R; Hereditary Endocrine Cancer Group, Spanish National Cancer Research Centre (CNIO), Madrid, Spain.
  • Calsina B; Hereditary Endocrine Cancer Group, Spanish National Cancer Research Centre (CNIO), Madrid, Spain.
  • Letón R; Hereditary Endocrine Cancer Group, Spanish National Cancer Research Centre (CNIO), Madrid, Spain.
  • Comino-Méndez I; Hereditary Endocrine Cancer Group, Spanish National Cancer Research Centre (CNIO), Madrid, Spain.
  • Roldán-Romero JM; Hereditary Endocrine Cancer Group, Spanish National Cancer Research Centre (CNIO), Madrid, Spain.
  • Montero-Conde C; Hereditary Endocrine Cancer Group, Spanish National Cancer Research Centre (CNIO), Madrid, Spain.
  • Santos M; Hereditary Endocrine Cancer Group, Spanish National Cancer Research Centre (CNIO), Madrid, Spain.
  • Pérez LI; Hereditary Endocrine Cancer Group, Spanish National Cancer Research Centre (CNIO), Madrid, Spain.
  • Pita G; Human Genotyping Unit-CeGen, Human Cancer Genetics Programme, Spanish National Cancer Research Centre (CNIO), Madrid, Spain.
  • Alonso MR; Human Genotyping Unit-CeGen, Human Cancer Genetics Programme, Spanish National Cancer Research Centre (CNIO), Madrid, Spain.
  • Honrado E; Anatomical Pathology Service, Hospital de León, León, Spain.
  • Pedrinaci S; Department of Genetics, Hospital Universitario Virgen de las Nieves, Granada, Spain.
  • Crespo-Facorro B; University of Cantabria and HU Marqués de Valdecilla-IDIVAL, CIBER Mental Health Santander, Santander, Spain.
  • Percesepe A; Medical Genetics, Department of Medicine and Surgery, University of Parma, Parma, Italy.
  • Falcioni M; Otolaryngology and Otoneurosurgery Department, Azienda Ospedaliero-Universitaria di Parma, Parma, Italy.
  • Rodríguez-Perales S; Molecular Cytogenetics Unit, Human Cancer Genetics Programme, Spanish National Cancer Research Centre (CNIO), Madrid, Spain.
  • Korpershoek E; Department of Pathology, Erasmus Medical Center Cancer Institute, University Medical Center Rotterdam, Rotterdam, The Netherlands.
  • Ramón-Maiques S; Structural Bases of Genome Integrity Group, Structural Biology and Biocomputing Programme, Spanish National Cancer Research Centre (CNIO), Madrid, Spain.
  • Opocher G; Veneto Institute of Oncology, Istituto di Ricovero e Cura a Carattere Scientifico, Padua, Italy.
  • Rodríguez-Antona C; Hereditary Endocrine Cancer Group, Spanish National Cancer Research Centre (CNIO), Madrid, Spain.
  • Robledo M; Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER), Madrid, Spain.
  • Cascón A; Hereditary Endocrine Cancer Group, Spanish National Cancer Research Centre (CNIO), Madrid, Spain.
Genet Med ; 20(12): 1644-1651, 2018 12.
Article en En | MEDLINE | ID: mdl-29740169
ABSTRACT

PURPOSE:

The high percentage of patients carrying germline mutations makes pheochromocytomas/paragangliomas the most heritable of all tumors. However, there are still cases unexplained by mutations in the known genes. We aimed to identify the genetic cause of disease in patients strongly suspected of having hereditary tumors.

METHODS:

Whole-exome sequencing was applied to the germlines of a parent-proband trio. Genome-wide methylome analysis, RNA-seq, CRISPR/Cas9 gene editing, and targeted sequencing were also performed.

RESULTS:

We identified a novel de novo germline mutation in DNMT3A, affecting a highly conserved residue located close to the aromatic cage that binds to trimethylated histone H3. DNMT3A-mutated tumors exhibited significant hypermethylation of homeobox-containing genes, suggesting an activating role of the mutation. CRISPR/Cas9-mediated knock-in in HeLa cells led to global changes in methylation, providing evidence of the DNMT3A-altered function. Targeted sequencing revealed subclonal somatic mutations in six additional paragangliomas. Finally, a second germline DNMT3A mutation, also causing global tumor DNA hypermethylation, was found in a patient with a family history of pheochromocytoma.

CONCLUSION:

Our findings suggest that DNMT3A may be a susceptibility gene for paragangliomas and, if confirmed in future studies, would represent the first example of gain-of-function mutations affecting a DNA methyltransferase gene involved in cancer predisposition.
Asunto(s)
Palabras clave

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Paraganglioma / Feocromocitoma / Neoplasias de las Glándulas Suprarrenales / ADN (Citosina-5-)-Metiltransferasas Tipo de estudio: Prognostic_studies Límite: Adult / Female / Humans / Male Idioma: En Año: 2018 Tipo del documento: Article

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Paraganglioma / Feocromocitoma / Neoplasias de las Glándulas Suprarrenales / ADN (Citosina-5-)-Metiltransferasas Tipo de estudio: Prognostic_studies Límite: Adult / Female / Humans / Male Idioma: En Año: 2018 Tipo del documento: Article